Results 71 to 80 of about 827 (180)

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Epidemiology and clinical significance of carbapenemases in Australia: a narrative review

Internal Medicine Journal, Volume 54, Issue 4, Page 535-544, April 2024.
Abstract Carbapenemase‐producing gram‐negative bacteria (CP‐GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP‐GNB infections reported was 907 in 2022), blaIMP‐4 has established low levels of endemicity in many states.
Abdullah Tarik Aslan, David L. Paterson
wiley   +1 more source

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +1 more source

<i>Ex vivo</i> assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations. [PDF]

Antimicrob Agents Chemother
ABSTRACT Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Abouelhassan Y, Shen Y, Chen A, Ye X, Nicolau DP, Kuti JL.   +5 more
europepmc   +3 more sources

Influence of Aging and Immune Alterations on Susceptibility to Pneumococcal Pneumonia in the Elderly. [PDF]

Pneumonia is a common respiratory infection affecting individuals of all ages, with a significantly higher incidence among the elderly. As the aging population grows, pneumonia is expected to become an increasingly critical health concern.
Agrawal, Anshu, Kang, Nathan, Subramanian, Veedamali   +2 more
core   +1 more source

Spontaneous bacterial peritonitis due to carbapenemase-producing Enterobacteriaceae: Etiology and antibiotic treatment [PDF]

, 2020
Carbapenem antibiotics were first introduced in the 1980s and have long been considered the most active agents for the treatment of multidrug-resistant gram-negative bacteria.
Alfieri A., Di Franco S., Fiore M., Leone S., Martora F., Pace M. C., Passavanti M. B., Petrou S.   +7 more
core   +1 more source

Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies

Microorganisms
This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases.
Majid Eslami, Amirabbas Safaripour, Seyedeh Zahra Banihashemian, Sahar Nikjoo Niaragh, Mohammad Amin Hemmati, Arefeh Shojaeian, Setayesh Fakhariyan, Atiye Rabbani, Valentyn Oksenych   +8 more
doaj   +1 more source

The changing landscape of antimicrobial resistance and use in South Africa: The need for access to new antibiotics: A position paper [PDF]

Antibiotic resistance is a global threat, with a disproportionate burden of mortality in low- and middle-income countries. It is increasing in both the public and private healthcare sectors within South Africa, especially in Gram-negative organisms, and ...
Chibabhai, V, Finlayson, H, Jeena, P, Kolman, S, Lowman, W, Manzini, T C, Nana, T, Nuttall, J, Parker, A, Skosana, P, Ueckermann, V, Wise, A   +11 more
core   +2 more sources

Nuevos inhibidores de β-lactamasas frente a patógenos gram negativos multirresistentes [PDF]

, 2022
Programa Oficial de Doutoramento en Ciencias da Saúde. 5007V01[Resumo] As especies Acinetobacter baumannii, Pseudomonas aeruginosa e a orde Enterobacterales son categorizados como patóxenos de prioridade crítica para o desenvolvemento de novos ...
Vázquez-Ucha, Juan Carlos
core  

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Microbiology Spectrum
Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-‍fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D. Perry, Mathias W. Pletz, Stefania Stefani, Ian Morrissey, Christopher Longshaw   +7 more
doaj   +1 more source